Abstracts by keywords: drugs
There has been a clear volume dynamic on the German pharmaceutical market for several years [1]. In addition, factors such as demographic change, medical-technical progress and the increase in outpatient therapy options lead to increasing pharmaceutical expenditure [2]. The legislature took up this progressive development by introducing the Medicines Market Reorganization Act (AMNOG) in 2011. Since then, new medications have been evaluated for their additional benefits. It turns out that a large number of new pharmaceutical products continue to come onto the German market, the additional benefit of which often cannot be proven or for which only a small additional benefit has been identified [3]. In addition, in the period from 2013 to the beginning of 2014, drugs that had already been approved were assessed as part of the AMNOG with regard to their additional benefit (so-called existing market call).1 The only group of active ingredients whose process was completed include the DPP-4 inhibitors (also gliptins).
06.12.2017
In statutory health insurance (GKV), service billing is carried out almost exclusively electronically, with service providers (e.g. doctors) extensively documenting the treatment of their patients according to precisely defined rules and then making this data available to the health insurance companies for billing purposes. Based on this routine data, a volume of more than 200 billion euros is billed annually for the entire statutory health insurance [1]. The purpose of GKV routine data is to bill GKV services [2]. However, this data can also be used as secondary data for many other purposes, such as in the context of health services research. Since billing data is usually available without any time or financial effort, there is increasing interest in the use of GKV routine data due to the latest health care reforms [3-6] and the reports of the Expert Council in the Health Care System [7-10]. In order to be able to use GKV routine data for scientific analyses, it must be clarified how valid such a secondary database is. This study therefore examined the question of the extent to which the billing data available to the health insurance companies on the use of medication by their insured persons corresponds to the actual medication taken, which was known from primary data from a clinical study that had already been carried out.
03.04.2017
When evaluating new drugs for the treatment of cancer, the endpoint survival is the main focus. Many of these new drugs can be shown to have a survival advantage compared to the previously available treatment options. However, it is often emphasized that this is usually only “two to three months” (e.g. Lauterbach 2015, Fojo et al. 2014). This additional survival time is often perceived as insufficient and complaints are also made that the time gained in this way often does not provide an adequate quality of life. Furthermore, the new active ingredients have not been sufficiently tested. The use of the usually high-priced drugs is therefore often not worth the money. Due to the high health policy importance of the assumption that new therapies only offer "two to three months" additional survival time, this study should examine whether this common assumption is in line with the facts. The basis for this is the resolutions for the evaluation of new drugs according to the Drug Market Reorganization Act (AMNOG), which all new active ingredients have had to undergo since 2011 in order to demonstrate their additional benefit compared to the so-called appropriate comparative therapy.
31.03.2016
Providing Multiple Sclerosis Patients with Ready-to-Use Cannabis Medicinal Products. Spasticity is one of the most significant symptoms of multiple sclerosis (MS), which is associated with significant limitations in daily life. Cannabis has been discussed for some time as a possible option for inadequately treatable spasticity, but for a long time, there were no approved preparations in Germany. This changed in the middle of last year, when […]
25.09.2012
The instrument of drug discount contracts was implemented in the statutory health insurance (GKV) system in order to curb drug spending in the outpatient sector. The GKV Competition Strengthening Act (GKV-WSG), which came into force on April 1, 2007, paved the way for health insurance companies to be able to conclude discount agreements with pharmaceutical manufacturers more effectively than before. Since then, pharmacists have had to give preference to discounted medications. Ideally, both manufacturers and health insurance companies can benefit from such discount agreements.
01.06.2010
The past and presumably also the current reforms of politics in the pharmaceutical sector strengthen the service providers working in the field of discount agreements according to §130a SGB V for the GKV. The reason for this lies essentially in the complexity of the materials as well as in the bundling of demand volumes. Despite the merger of several health insurance companies, however, they wish to see their individual interests reflected in the contract. Service providers like GWQ ServicePlus AG are measured by whether they enable individual contract strategies in the pharmaceuticals sector on the one hand and whether they successfully achieve high discounts on the other. This is accompanied by the complex task of the technical implementation of the contracts and also a far-reaching consulting service on drug contracts. This concerns pharmaceutical, procurement law, data technology and financial aspects.